Fentanylization of Kratom: A narrative mini-review of escalating potency, access, and psychiatric complications

Recreational substance use in the United States trends towards increasingly concentrated products, including fentanyl, cannabis oils, and nicotine-salts.Concentrated and semi-synthetic alkaloids derived from the Mitragyna speciosa (Kratom) plant represent emerging substances of misuse due to accessibility and limited regulation.Available evidence suggests potential drug-drug interactions between Kratom alkaloids and psychiatric medications, as well as associations with psychiatric symptoms, withdrawal, dependence, and overdose.This review synthesizes the United States regulatory and market landscape and the psychiatric clinical, pharmacologic, and pharmacokinetic evidence regarding recreational Kratom alkaloid use.It introduces the term "fentanylization" as a framework for understanding how the escalating potency of Kratom products mirrors that of other concerning substances of misuse.We completed a narrative mini-review of PubMed, Google Scholar, and relevant United States government databases in September, 2026.Core adverse-outcome and pharmacology terms included "Kratom alkaloids", "7hydroxymitragynine", "mitragynine pseudoindoxyl", "Kratom drug interactions", "Kratom serotonin syndrome", "mitragynine CYP450", "Kratom psychosis", and "Kratom toxicity".To balance the search, additional pertinent terms were included, such as "Kratom therapeutic use", "Kratom pharmacokinetics", "mitragynine whole leaf", "Kratom epidemiology", and "Kratom opioid use disorder treatment".Limitations of narrative mini-reviews include author selection bias, nonreproducibility, and limited scope compared to traditional narrative reviews.Our search identified 400 scientific articles published between 2021 and 2026, compared with 244 publications from 1985 through 2020.Pharmacokinetic and pharmacologic research indicates Kratom, Kratom alkaloid extracts, and semi-synthetic alkaloids may carry health implications for consumers, including activity at mu-opioid receptors and inhibition or modulation of cytochrome P450 enzymes.Case reports describe Kratom-associated serotonin toxicity, psychosis, and mania, as well as risk for withdrawal, dependence, and overdose, though causation remains ill defined.The use of concentrated and semi-synthetic Kratom alkaloids poses a potential risk to consumers, particularly those with psychiatric disorders, though evidence of this risk is low quality and primarily focused on in vitro, animal, and case studies.These substances appear to follow a pattern of increasingly potent products that are easily available for consumer purchase.Clinicians should screen for and consider patients' Kratom usage when evaluating new symptoms and changing medications in psychiatric settings.